Such potential new opportunities include, in addition to itch and pain, cognitive enhancement by inverse agonists at α5 GABAARs48,49, depression and autism spectrum disorders (for a review see ref. 50). This evidence concerns the gene IGKV2D-26 and depressive symptom measurement.